



# Liquid Biopsies

**Next Generation Cancer Molecular Diagnostics**




**INVESTOR**  
FORUM

October 20-21, 2015  
San Francisco, CA


*Accelerate discovery.  
Amplify returns.*

# Forward Looking Statements



Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology under development, clinical development of diagnostic tests, and potential opportunities for OncoCyte Corporation and the diagnostic tests it is developing, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “may,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development, testing, marketing and/or commercialization of potential diagnostic tests, including developing or obtaining the resources and capabilities required to do so, uncertainty in the results of clinical trials, need and ability to obtain future capital, and maintenance of intellectual property rights, need to obtain approvals from federal and state regulatory agencies, and uncertainty as to reimbursements or coverage from third party payers such as Medicare, health insurance companies, and health maintenance organizations. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the Risk Factors and other cautionary statements found in the registration statement on Form 10 and the Information Statement included therein as an exhibit, filed by OncoCyte with the Securities and Exchange Commission. OncoCyte disclaims any intent or obligation to update these forward-looking statements and/or this presentation, including but not limited to any changes resulting from changes in fact or circumstances.

This presentation is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of OncoCyte Corporation.



## **Our Vision**

Developing highly accurate, simple to use liquid biopsy cancer diagnostics


## **Our Mission**

Revolutionizing cancer diagnostics through the use of non-invasive liquid biopsies to support clinicians, improve health outcomes and reduce cost of care

## **Our Science**


Leveraging our core competencies in biomarker discovery and gene expression classifiers along with our relationships with leading scientific institutions to create a robust pipeline

# Investment Highlights



- Positioned to capitalize on standard of care moving to liquid biopsy molecular diagnostics
- Large target market of 13-16M annual lung and breast patients
- High level of payer and HCP interest due to unmet medical needs
- On track for first product launch
- Clinical data presented at major meetings with ongoing clinical research and trials at leading scientific institutions
- Strong pipeline of other products leverages core R&D competencies
- Robust IP portfolio for multiple indications
- Experienced leadership team with diagnostics, commercial expertise
- Form 10 filed with the SEC on October 7, 2015

# Molecular diagnostics evolving to non-invasive liquid biopsies




## IMAGING



Mammogram  
LDCT

## TISSUE BIOPSY




Veracyte  
Genomic Health



## LIQUID BIOPSY




# Molecular diagnostics are projected to grow at 15% CAGR over the next 10 years



2014 Diagnostics Market Share




MDx Forecast 2024




U.S. Accounts for over 50% of global sales

The fastest growing segment is expected to be oncology

# Focus on two largest segments of cancer diagnostics





- Lung and breast are ~50% of total global diagnostics revenue




Cancer Diagnostics Market: Global Industry Analysis, Size, Share, and Forecast 2014-2020, Transparency Market Research  
Diagnostics include both imaging and molecular diagnostics

# Product pipeline focused on greatest unmet need



# Lung cancer opportunity driven by poor outcomes




Lung cancer is typically diagnosed at later stages

- Projected to kill 158K people in US in 2015
- Overall cost >\$12B
- Survival rates have seen minimal increases


Stage	Incidence	Survival Rate
Overall		17.4%
Local (Early stages)	16%	54.8% IA 75% IB 71% IIA 58% IIB 49%
Regional (Stage III)	22%	27.4%
Distant (Stage IV)	57%	4.2%

5 Yr Survival Rate



Sources: Cancer of the Lung and Bronchus SEER Stat Fact Sheets  
 NCCN Guidelines Lung Cancer Screening 2/2014  
 USPSTF Screening for Lung Cancer

# Today's standard of care for lung is driving health care costs higher



USPSTF guidelines Patients with 30 pack-year history recommended for LDCT annually


- 7-10M Americans

LDCT has high rate of false positives

- 25% indeterminate of which 96% false positive
- Indeterminate diagnosis requires additional procedures



# Indeterminate diagnoses results in unnecessary patient risk





## Downstream procedures can be risky for patients



- Bronchoscopies
- Surgery
- Needle biopsy
- Radiation exposure

## Invasive procedures can result in morbidity and mortality

- 0.5 to 1% mortality
- 4-20% major complications
- 2-15% collapsed lung




# Potential to eliminate ~2M unnecessary lung procedures while improving standard of care




TAM numbers based on company estimates and secondary data


# Leveraging a common liquid biopsy strategy for several oncology indications: Lung, Breast and Bladder




## Diagnostic Strategy




# OncoCyte Diagnostic would reduce the number of false positives sent to follow-up invasive testing





## Lung Cancer Diagnostics






- The Wistar Institute in the lab of Dr. Louise C. Showe
- 8+ years of developing blood-based tests for lung cancer
- Significant sample access (>2000 samples and ongoing collection)
- OncoCyte exclusive option and ongoing SRA
- Strategy: leverage SRA and relationship with Wistar
- In-license technology

# Lung preliminary assay showed strong performance with initial biomarkers and classifier



- Prototype classifier presented at ATS in 2015
- Sensitivity: 76%
- Specificity: 88%

# Commercialization strategy addresses key stakeholders



## Benefits

### HCP

- Determinate diagnosis
- High sensitivity
- High specificity
- Reduce unnecessary procedures

### Patient

- Earlier detection
- Improved outcomes
- Reduce anxiety over indeterminate finding

### Payer

- Improved health outcomes
- Fewer unnecessary procedures
- Reduce overall costs


## Marketing Strategy

- Specialty sales force
- TPP refinement via market research
- Practice guidelines
- Peer review journals
- KOL influence


- Reimbursement support out of pocket
- Increase awareness to increase LDCT uptake: advocacy groups PSAs, public relations

- Pricing vs comparator
- RWE clinical utility studies
- Reimbursement support
- CMS 1<sup>st</sup> coverage focus
- Managed Medicaid contract
- 5 Largest health plans

# Lung and breast unmet diagnostic needs resonate with Payers



Payer Diagnostic Unmet Need




“Lung has the highest unmet need due to false positives in workups.”

“Lung is the one to go for – greater prevalence, greater mortality and greater need for better screening.”

- Payers gave lung and breast diagnostic high unmet needs
- Pricing and TPP discussion with payers very positive

Asked of 10 Commercial, Managed Medicaid and Managed Medicare payers representing 20M covered lives  
Q8: Now I would like to ask what is your perception of the overall unmet need for certain oncology screening diagnostics or procedures.  
On a scale of 1 to 10 where 1 is no unmet need and 10 is significant unmet need for an improved screening procedure/diagnostic


# OncoCyte has filed aggressively for patent protection in key jurisdictions



Patent Family	Pending and Issued		Priority Date	Indication
	US	EX US		
Onco-040	P	-	2012	Breast
Onco-052	P	7 P	2011	
Onco-050	P	1 I/4 P	2011	Bladder
Onco-056	P	7 P	2011	
Onco-060	P	P (PCT)	2013	
Onco-065	P(PRV)	To be filed	2015	
WST123*	1 P/1 I P(PRV)	4 I/2 P To be filed	2007 2015	Lung
Onco-053	P	-	2012	Other Solid Tumors (Pancreatic, Thyroid, Ovarian, Colorectal)
Onco-054	P	-	2012	
Onco-057	P	-	2011	
Onco-058	P	7 P	2011	
Onco-059	P	7P	2011	Pan Cancer
Onco-064	P	P(PCT)	2013	


\*Exclusive options executed; licensing agreement under development

# Experienced management team in place



	<b>Position</b>	<b>Experience</b>
<b>William Annett</b>	CEO	CEO BioFX Labs; CEO Corra Life Sciences; Managing Director Accenture Life Sciences; Head Commercial Strategy and Project Finance Genentech; Harvard MBA
<b>Karen Chapman</b>	VP Research	Advanced Cell Technology, Origen Therapeutics, Geron Corporation, Ph.D. Johns Hopkins University School of Medicine
<b>Kristine Mechem</b>	VP Marketing and Planning	Business Analytics Abbott Labs; Marketing Planning Genentech, Managed Care consulting, VP Marketing and Business Development Corra Life Sciences
<b>Lyssa Friedman</b>	VP Clinical Operations	Veracyte VP Clinical OPs, Telomere Diagnostics, VP Clinical Development Carmenta Biosciences, McKesson Oncology Network, Oncology RN
<b>William Seltzer</b>	VP Clinical Services	Veracyte, Illumina, Counsyl, Athena Diagnostics

# Investment Highlights



- Positioned to capitalize on standard of care moving to liquid biopsy molecular diagnostics
- Large target market of 13-16M annual lung and breast patients
- High level of payer and HCP interest due to unmet medical needs
- On track for first product launch
- Clinical data presented at major meetings with ongoing clinical research and trials at leading scientific institutions
- Strong pipeline of other products leverages core R&D competencies
- Robust IP portfolio for multiple indications
- Experienced leadership team with diagnostics, commercial expertise



# Liquid Biopsies

## Next Generation Cancer Molecular Diagnostics

William Annett

Chief Executive Officer

[wannett@oncocyte.com](mailto:wannett@oncocyte.com)

415.609.1674 mobile

510.775.0490 office